Summary of COVID-19 cannabidiol studies

2,424 patient cannabidiol prophylaxis study: 50% fewer cases (p=0.006).
Retrospective 1,212 patients in the USA with a history of seizure-related conditions, showing patients treated with CBD100 had significantly lower incidence of COVID-19 cases compared to a matched control group. In Vitro study showing CBD inhibits SARS-CoV-2 with Vero E6 and Calu-3 cells. Mouse study showing CBD significantly inhibited viral replication in the lung and nasal turbinate. Authors note that CBD does not inhibit ACE2 expression or the main viral proteases, inhibition occurs after viral entry. Authors stress several limitations for use at this time, including purity, quality, and the formulation of products, and potential lung damage based on administration method. Authors recommend clinical trials, but do not mention the existing RCT by Crippa et al.
Jan 2022, Science Advances, https://www.science.org/doi/10.1126/sciadv.abi6110, https://c19p.org/nguyen

2. Mannumbeth Renjithlal et al., Cannabis Use and COVID-19 Hospitalization Outcomes. A Retrospective Study

39,285 patient cannabidiol prophylaxis PSM study: 56% lower mortality (p<0.0001), 25% lower ventilation (p<0.0001), and 6% longer hospitalization (p=0.0009).
Retrospective 1,657,800 COVID-19 hospitalizations in the USA including 13,095 patients with cannabis use disorder, showing lower risk of mortality with cannabis use disorder. The text and Table S2 have conflicting results for mortality: 0.45 [0.36-0.57] versus 0.43 [0.34-0.55].
Jan 2023, SSRN Electronic J., https://www.ssrn.com/abstract=4336513, https://c19p.org/mannumbethrenjithlal

3. Shover et al., Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis

1,831 patient cannabidiol prophylaxis PSM study: 2% lower mortality (p=0.57), 5% lower ventilation (p=0.02), 9% lower ICU admission (p=0.02), and 3% lower need for oxygen therapy (p=0.27).
Retrospective 1,831 hospitalized COVID-19 patients in the USA, showing lower mechanical ventilation and ICU admission, but no significant difference in mortality.
Aug 2022, J. Cannabis Research, https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-022-00152-x, https://c19p.org/shover

4. Griffith et al., Cannabis, Tobacco Use, and COVID-19 Outcomes

72,501 patient cannabidiol prophylaxis study: 3% lower mortality (p=0.73), 27% higher ICU admission (p<0.0001), and 80% higher hospitalization (p<0.0001).
Retrospective 72,501 COVID-19 patients in the USA showing cannabis use associated with higher risk of hospitalization and ICU admission.
Jun 2024, JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820235, https://c19p.org/griffith

5. Lehrer et al., Association of cannabis with chronic obstructive pulmonary disease and COVID-19 infection

cannabidiol prophylaxis study: 24% more cases (p=0.009).
UK Biobank retrospective showing a higher risk of COVID-19 cases with a history of cannabis use.
Jun 2022, Chronic Diseases and Translational Medicine, https://onlinelibrary.wiley.com/doi/10.1002/cdt3.38, https://c19p.org/lehrer2

6. Huang et al., Cannabis use is associated with lower COVID-19 susceptibility but poorer survival

13,099 patient cannabidiol prophylaxis study: 181% higher mortality (p=0.04) and 19% fewer cases (p=0.0001).
UK Biobank retrospective with 13,099 cannabis users, showing a lower risk of COVID-19 infection, however regular users had a significantly higher risk of mortality.
Mar 2022, Frontiers in Public Health, https://www.frontiersin.org/articles/10.3389/fpubh.2022.829715/abstract, https://c19p.org/huang2

7. Merianos et al., Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among student e-cigarette users at four U.S. Universities

800 patient cannabidiol prophylaxis study: 212% more symptomatic cases (p<0.0001) and 3% more cases (p=0.33).
Retrospective 800 e-cigarette users in the USA, showing higher risk of COVID-19 diagnosis and symptoms with cannabis use.
Mar 2022, Addictive Behaviors, https://www.sciencedirect.com/science/article/pii/S0306460321003555, https://c19p.org/merianos

8. Crippa et al., Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

91 patient cannabidiol late treatment RCT: 557% higher hospitalization (p=0.25) and 33% slower recovery (p=0.21).
RCT 105 patients recruited in an ER in Brazil, 49 treated with CBD, showing no significant differences with treatment. 300mg CBD for 14 days. For discussion see [liebertpub.com].
Oct 2021, Cannabis and Cannabinoid Research, https://www.liebertpub.com/doi/full/10.1089/can.2021.0093, https://c19p.org/crippa

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0